

**APPOINTMENT OF MEDIPROUD CO., LTD AS NON-EXCLUSIVE DISTRIBUTOR
FOR BIOLIDICS' NOVEL CORONAVIRUS 2019 ANTIBODY TEST KITS**

The board of directors (the "**Board**" or the "**Directors**") of Biolidics Limited (the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to announce that the Company had, on 7 May 2020, entered into a distribution agreement (the "**Agreement**") with Mediproud Co., Ltd ("**Mediproud**"), a company incorporated in Thailand, to appoint Mediproud as a non-exclusive distributor for the Company's test kits for the detection of the Novel Coronavirus 2019 antibodies (the "**COVID-19 Antibody Test Kits**"), in Thailand for a duration of one year from the date of the Agreement. The Company's COVID-19 Antibody Test Kits are for the qualitative detection of the antibodies to SARS-CoV-2 (the virus which causes the disease, the Novel Coronavirus 2019), IgG and IgM, in human serum, plasma and whole blood.

Under the terms of the Agreement, among others, Mediproud shall assist the Company to obtain all permits, licenses, registrations and consents from the applicable authorities in order to import and sell the COVID-19 Antibody Test Kits in Thailand. Mediproud is in the process of obtaining the Thailand Food and Drug Administration's ("**Thailand FDA**") authorisation to offer the COVID-19 Antibody Test Kits in Thailand. The use of the COVID-19 Antibody Test Kits in Thailand will be limited to testing in laboratories or by healthcare workers at the point-of-care.

Incorporated in 2015, Mediproud is a distributor of medical equipment and tools in Thailand. For more information on Mediproud, please visit <https://www.mediproud.com/home>.

The Agreement is likely to contribute positively to the revenue of the Group for the current financial year ending 31 December 2020 ("**FY2020**"). However, the Company is unable to quantify the financial impact for FY2020 as the volume and timing of the orders by Mediproud cannot be determined as at the date of this announcement.

Shareholders and potential investors should note that the import and sale of the Company's COVID-19 Antibody Test Kits in Thailand is subject to its COVID-19 Antibody Test Kits obtaining all permits, licenses, registrations and consents from the applicable authorities in Thailand, and in particular, the authorisation of the Thailand FDA ("**Regulatory Approvals**"). There is no certainty that such Regulatory Approvals will be obtained.

Further, shareholders and potential investors should note that policies in relation to diagnosis and/or detection of the Novel Coronavirus 2019 virus and/or antibodies in various jurisdictions may change in response to developments in the COVID-19 situation which is evolving rapidly. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

Save for their respective shareholdings in the Company (if any), the Company is not aware of any of its Directors or substantial shareholders having any interest, direct or indirect in the Agreement.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Non-Executive Non-Independent Chairman
8 May 2020

This announcement has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.